Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Topical Ruxolitinib (Jak1/Jak2 Inhibitor) in Chronic Hand Dermatitis Attenuates Inflammation and Enhances Skin Barrier Repair

NCT05293717 is registered in ClinicalTrials.gov with University of Rochester as lead sponsor.

NCT NCT05293717
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05293717 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Topical Ruxolitinib (Jak1/Jak2 Inhibitor) in Chronic Hand Dermatitis Attenuates Inflammation and Enhances Skin Barrier Repair
Lead sponsor
University of Rochester
Phase
Phase 1/2
Overall status
Completed
Start date
July 11, 2022
Completion date
December 31, 2024
Enrollment
16 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hand dermatitis